Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria

Only a small proportion of patients with triple-negative breast cancer benefit from immune checkpoint inhibitor (ICI) targeting PD-1/PD-L1 signaling in combination with chemotherapy. Here, we discovered that therapeutic response to ICI plus paclitaxel was associated with subcellular redistribution o...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Xiao-Qing, Yang, Yi, Wang, Qiang, Liu, Hao-Fei, Fang, Xuan-Yu, Li, Cheng-Long, Jiang, Yi-Zhou, Wang, Shuai, Zhao, Hong-Yu, Miao, Jing-Ya, Ding, Shuai-Shuai, Liu, Xin-Dong, Yao, Xiao-Hong, Yang, Wen-Tao, Jiang, Jun, Shao, Zhi-Ming, Jin, Guoxiang, Bian, Xiu-Wu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977947/
https://www.ncbi.nlm.nih.gov/pubmed/36627348
http://dx.doi.org/10.1038/s41422-022-00766-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977947/
https://www.ncbi.nlm.nih.gov/pubmed/36627348
http://dx.doi.org/10.1038/s41422-022-00766-z

Ejemplares similares